# Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM

> **NCT05914662** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 42 (estimated)

## Conditions studied

- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** Zanubrutinib, Bendamustine and Rituximab

## Key facts

- **NCT ID:** NCT05914662
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-15
- **Primary completion:** 2025-03-15
- **Final completion:** 2025-12-15
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05914662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05914662, "Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05914662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*